First batch of EpiVacCorona vaccine from Vektor center has arrived in Bashkiria
The first batch of EpiVacCorona vaccine, developed at the Vektor State Research Center of Virology and Biotechnology of Rospotrebnadzor in Novosibirsk, has arrived in Bashkiria.
According to the press secretary of the Ministry of Health of the Republic, Sofya Aleshina, the first batch of EpiVacCorona covid vaccine in the amount of 3240 doses arrived in the region today.
The vaccine is administered twice with an interval between jabs of 14 to 21 days.
The drug has successfully passed clinical trials and was registered for use in Russia on October 13, 2020. Clinical trials are carried out at 9 medical institutions in Moscow, the Moscow region, Kazan, Tyumen, Kaliningrad with the participation of volunteers aged 18 and over, as well as in the Novosibirsk region (in volunteers over 60).
Contraindications for its use are:
• Hypersensitivity to the components of the drug (aluminum hydroxide and others).
• Severe forms of allergic diseases.
• Reaction or post-vaccination complication to previous vaccine administration.
• Acute infectious and non-infectious diseases, chronic diseases in the acute stage — vaccinations are carried out no earlier than a month after recovery or remission. With mild ARVI, acute infectious diseases of the gastrointestinal tract, vaccination is carried out after the temperature has returned to normal.
• Immunodeficiency (primary).
• Malignant blood diseases and neoplasms.
• Pregnancy and the period of breastfeeding.
• Children under 18 years of age (due to lack of efficacy and safety data).